Celera is a molecular diagnostics business with powerful discovery platforms dedicated to the practice of Targeted Medicine. Located in Rockville, MD and Alameda, CA, the company employs about 300 people and has the full capability to discover, develop, manufacture and secure registration for In Vitro Diagnostic products.
To identify novel diagnostic markers and potential drug targets, we are leveraging capabilities in proteomics, genomics and bioinformatics to better understand the association between common diseases (cardiovascular, autoimmune and cancer) and patterns of genetic variation and protein expression. Our strategy is to be a leader in Targeted Medicine by producing new genetic and proteomic-based diagnostics tests that improve patient outcome by predicting disease risk, selecting the most effective therapy and monitoring treatment. Another goal is to capitalize on the value of our discoveries through partnerships to develop new therapies, identify new disease indications for existing drugs, and to provide pharmacogenomic and companion diagnostic tests.
Celera has a strategic alliance with Abbott Laboratories through which the companies sell and support molecular diagnostic products. Celera's discovery platforms are the basis for multiple discovery and therapeutic product development collaborations.